Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-line treatment for patients with hypertension: An ALLHAT analysis

被引：0
|
作者：
Heidenreich, PA
Davis, BR
Furberg, CD
Lairson, DR
Pressel, S
Goldman, L
机构：
[1] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2006年 / 47卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：372A / 372A
页数：1
相关论文
共 50 条
  • [31] THE COST-EFFECTIVENESS OF PEGASPARGASE FOR FIRST-LINE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA: A COST-UTILITY ANALYSIS
    Basu, S.
    Lin, P. L.
    Rowntree, C.
    Saha, V.
    HAEMATOLOGICA, 2017, 102 : 598 - 599
  • [32] Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma - A lifetime cost-effectiveness analysis
    Messori, A
    Cecchi, M
    Becagli, P
    Trippoli, S
    CANCER, 1997, 79 (11) : 2264 - 2266
  • [33] COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB MAINTENANCE TREATMENT OF FOLLICULAR LYMPHOMA IN PATIENTS RESPONDING TO FIRST-LINE INMUNOCHEMOTHERAPY INDUCTION
    Castro-gomez, A. J.
    Lopez-Guillermo, A.
    Rueda, A.
    Salar, A.
    Rubio-Terres, C.
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
  • [34] Cost-Effectiveness Analysis of Entecavir versus Lamivudine in the First-Line Treatment of Australian Patients with Chronic Hepatitis B
    Arnold, Elizabeth
    Yuan, Yong
    Iloeje, Uchenna
    Cook, Greg
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2008, 6 (04) : 231 - 246
  • [35] Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B
    Elizabeth Arnold
    Yong Yuan
    Uchenna Iloeje
    Greg Cook
    Applied Health Economics and Health Policy, 2008, 6 (4) : 231 - 246
  • [36] COST-EFFECTIVENESS ANALYSIS OF FILGOTINIB AS A FIRST-LINE TREATMENT FOR BIOLOGIC-NAIVE PATIENTS WITH ULCERATIVE COLITIS IN GREECE
    Nomikos, N.
    Naoum, P.
    Athanasakis, K.
    Kyriopoulos, I
    VALUE IN HEALTH, 2024, 27 (12) : S80 - S80
  • [37] Pharmacoeconomic profile of Paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma - A lifetime cost-effectiveness analysis
    Messori, A
    Trippoli, S
    Becagli, P
    Tendi, E
    CANCER, 1996, 78 (11) : 2366 - 2373
  • [38] A cost-effectiveness analysis of first-line controller therapies for persistent asthma
    Shih, Ya-Chen Tina
    Mauskopf, Josephine
    Borker, Rohit
    PHARMACOECONOMICS, 2007, 25 (07) : 577 - 590
  • [39] A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma
    Ya-Chen Tina Shih
    Josephine Mauskopf
    Rohit Borker
    PharmacoEconomics, 2007, 25 : 577 - 590
  • [40] Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran
    Fariman, Soroush
    Nasab, Fatemeh Momeni
    Faraji, Hoda
    Afzali, Monireh
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 38 : 93 - 100
12345